Allogene Therapeutics (ALLO) furnishes Q2 2025 results and corporate update

Rhea-AI Filing Summary

Allogene Therapeutics, Inc. filed a current report to note that it has released a corporate update and its financial results for the quarter ended June 30, 2025. The details are contained in a press release dated August 13, 2025, which is included as Exhibit 99.1 and incorporated by reference.

The company specifies that this information is being furnished under the rules of the Securities Exchange Act and is not deemed filed for liability purposes. The filing is signed by President and Chief Executive Officer David Chang, M.D., Ph.D.

0001737287FALSE00017372872025-05-132025-05-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________

FORM 8-K

____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

_______________________

Allogene Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

____________________________

Delaware			001-38693			82-3562771
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

210 East Grand Avenue, South San Francisco, California 94080

(Address of principal executive offices including zip code)

Registrant’s telephone number, including area code: (650) 457-2700

(Former name or former address, if changed since last report.)

________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form 8-K):

			☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
			☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
			☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
			☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

ALLO

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02    Results of Operations and Financial Condition.

On August 13, 2025, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended June 30, 2025 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.

The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits.

(d)
Exhibit Number						Description
99.1						Press Release of the Company, dated August 13, 2025.
104						The cover page of this report has been formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ALLOGENE THERAPEUTICS, INC.
			By:			/s/ David Chang, M.D., Ph.D.
						David Chang, M.D., Ph.D.
						President, Chief Executive Officer

Dated: August 13, 2025

FAQ

What did Allogene Therapeutics (ALLO) disclose in this 8-K?

Allogene Therapeutics furnished a press release providing a corporate update and its financial results for the quarter ended June 30, 2025, as Exhibit 99.1.

Which period do the Allogene Therapeutics (ALLO) results in this 8-K cover?

The results relate to the company’s financial performance for the quarter ended June 30, 2025.

How did Allogene Therapeutics (ALLO) provide its quarterly results?

The company issued a press release dated August 13, 2025, attached to the report as Exhibit 99.1 and incorporated by reference.

Is the Allogene Therapeutics (ALLO) earnings information considered filed with the SEC?

The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and therefore is not subject to Section 18 liability of the Exchange Act.

Who signed this Allogene Therapeutics (ALLO) 8-K?

The report was signed on behalf of Allogene Therapeutics, Inc. by David Chang, M.D., Ph.D., its President and Chief Executive Officer.